Intrexon Corporation (NYSE:XON) had its target price lowered by Bank of America Corporation from $25.00 to $21.00 in a research note issued to investors on Friday. The brokerage currently has a neutral rating on the biotechnology company’s stock.
Several other brokerages also recently weighed in on XON. Zacks Investment Research downgraded Intrexon Corporation from a hold rating to a sell rating in a report on Thursday, July 13th. Northland Securities set a $30.00 price target on Intrexon Corporation and gave the stock a buy rating in a report on Monday, August 7th. BidaskClub downgraded Intrexon Corporation from a hold rating to a sell rating in a report on Friday, August 4th. Griffin Securities restated a buy rating and set a $55.00 price target on shares of Intrexon Corporation in a report on Friday, October 6th. Finally, JMP Securities restated an outperform rating and set a $42.00 price target on shares of Intrexon Corporation in a report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the company. The stock presently has an average rating of Hold and an average price target of $38.50.
Intrexon Corporation (NYSE XON) traded down $4.07 on Friday, reaching $11.81. The company had a trading volume of 8,798,000 shares, compared to its average volume of 1,082,662. Intrexon Corporation has a 1 year low of $11.80 and a 1 year high of $32.90. The company has a current ratio of 2.45, a quick ratio of 2.25 and a debt-to-equity ratio of 0.01.
Intrexon Corporation (NYSE:XON) last posted its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. Intrexon Corporation had a negative return on equity of 18.59% and a negative net margin of 66.88%. The firm had revenue of $54.40 million for the quarter, compared to analyst estimates of $57.17 million. During the same quarter in the prior year, the company earned ($0.42) EPS. Intrexon Corporation’s revenue was up 3.6% on a year-over-year basis. equities analysts forecast that Intrexon Corporation will post -0.84 earnings per share for the current year.
WARNING: “Intrexon Corporation (XON) Price Target Cut to $21.00 by Analysts at Bank of America Corporation” was originally reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dispatchtribunal.com/2017/11/11/intrexon-corporation-xon-price-target-cut-to-21-00-by-analysts-at-bank-of-america-corporation.html.
In other Intrexon Corporation news, Director Robert B. Shapiro acquired 2,850 shares of the company’s stock in a transaction dated Tuesday, August 22nd. The shares were acquired at an average price of $17.50 per share, for a total transaction of $49,875.00. Following the acquisition, the director now owns 43,157 shares in the company, valued at approximately $755,247.50. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Andrew J. Last acquired 2,000 shares of the company’s stock in a transaction dated Monday, August 14th. The stock was acquired at an average price of $19.99 per share, for a total transaction of $39,980.00. Following the acquisition, the chief operating officer now owns 2,000 shares in the company, valued at approximately $39,980. The disclosure for this purchase can be found here. Corporate insiders own 55.10% of the company’s stock.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wells Fargo & Company MN increased its holdings in shares of Intrexon Corporation by 13.8% in the 3rd quarter. Wells Fargo & Company MN now owns 118,462 shares of the biotechnology company’s stock valued at $2,252,000 after acquiring an additional 14,333 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Intrexon Corporation by 7,504.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 59,622 shares of the biotechnology company’s stock valued at $1,122,000 after acquiring an additional 58,838 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Intrexon Corporation by 493.1% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,258 shares of the biotechnology company’s stock valued at $271,000 after acquiring an additional 11,854 shares during the last quarter. Dynamic Technology Lab Private Ltd increased its holdings in shares of Intrexon Corporation by 127.0% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 24,640 shares of the biotechnology company’s stock valued at $468,000 after acquiring an additional 13,783 shares during the last quarter. Finally, Macquarie Group Ltd. increased its holdings in shares of Intrexon Corporation by 25.7% in the 3rd quarter. Macquarie Group Ltd. now owns 35,995 shares of the biotechnology company’s stock valued at $684,000 after acquiring an additional 7,353 shares during the last quarter. Institutional investors and hedge funds own 82.10% of the company’s stock.
About Intrexon Corporation
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.